Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David V Sheehan

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
International Clinical Psychopharmacology|February 28, 2008
Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability ScaleKathy Harnett Sheehan, David V Sheehan
Psychopharmacology Bulletin|February 8, 2007
Current approaches to the pharmacologic treatment of anxiety disordersDavid V Sheehan, Kathy Harnett Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
Is a count of suicidal ideation and behavior events useful in assessing global severity of suicidality? A case studyJennifer M Giddens, David V Sheehan
Psychopharmacology Bulletin|October 21, 2003
Paroxetine treatment of generalized anxiety disorderDavid V Sheehan, C Gloria Mao
Handbook of Clinical Neurology|May 22, 2012
Generalized anxiety disorderRosario B Hidalgo, David V Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
How the Timing of a Patient's Self-ratings of Suicidality and the Relationship to the Recipient Affect Patient Responses: A Case StudyJennifer M Giddens, David V Sheehan
The Primary Care Companion for CNS Disorders|October 8, 2015
The Psychological and Medical Factors Associated With Untreated Binge Eating DisorderDavid V Sheehan, Barry K Herman
Innovations in Clinical Neuroscience|December 19, 2014
The complexity of assessing overall severity of suicidality: a case studyJennifer M Giddens, David V Sheehan
Psychiatry (Edgmont (Pa. : Township))|January 28, 2010
Benzodiazepines risk, abuse, and dependence: a tsunami in a tea cupRosario B Hidalgo, David V Sheehan
Managed Care Quarterly|December 13, 2002
Impact of formulary restrictions on the cost-effectiveness of antidepressant treatmentDavid V Sheehan, Pamela J Wright-Etter
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
International Clinical Psychopharmacology|February 28, 2008
Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability ScaleKathy Harnett Sheehan, David V Sheehan
Psychopharmacology Bulletin|February 8, 2007
Current approaches to the pharmacologic treatment of anxiety disordersDavid V Sheehan, Kathy Harnett Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
Is a count of suicidal ideation and behavior events useful in assessing global severity of suicidality? A case studyJennifer M Giddens, David V Sheehan
Psychopharmacology Bulletin|October 21, 2003
Paroxetine treatment of generalized anxiety disorderDavid V Sheehan, C Gloria Mao
Handbook of Clinical Neurology|May 22, 2012
Generalized anxiety disorderRosario B Hidalgo, David V Sheehan
Innovations in Clinical Neuroscience|December 19, 2014
How the Timing of a Patient's Self-ratings of Suicidality and the Relationship to the Recipient Affect Patient Responses: A Case StudyJennifer M Giddens, David V Sheehan
The Primary Care Companion for CNS Disorders|October 8, 2015
The Psychological and Medical Factors Associated With Untreated Binge Eating DisorderDavid V Sheehan, Barry K Herman
Innovations in Clinical Neuroscience|December 19, 2014
The complexity of assessing overall severity of suicidality: a case studyJennifer M Giddens, David V Sheehan
Psychiatry (Edgmont (Pa. : Township))|January 28, 2010
Benzodiazepines risk, abuse, and dependence: a tsunami in a tea cupRosario B Hidalgo, David V Sheehan
Managed Care Quarterly|December 13, 2002
Impact of formulary restrictions on the cost-effectiveness of antidepressant treatmentDavid V Sheehan, Pamela J Wright-Etter
Pageof 9